1864results about "Compound screening" patented technology

The invention relates to the technical field of cytology, in particular to a grass carp brain astrocyte line and application thereof, the grass carp brain astrocyte line is preserved in China Center for Type Culture Collection on May 7, 2025, and the preservation number of the grass carp brain astrocyte line is CCTCC NO: C2025149. The grass carp brain astroglia cell line provided by the invention has the capability of efficiently proliferating GCRV-II, and the virus titer of the GCRV-II replicated in the cell line at least can reach 1.38 * 10 < 8 > pfu / mL or above; after the GCRV-II is blindly passed for 5 generations in a grass carp astroglia cell line, the grass carp can still have typical bleeding symptoms and death due to the virus. And the exogenous plasmid transfected grass carp brain astroglia cell line has similar transfection efficiency to commercial grass carp kidney cells. Therefore, the invention lays an important foundation for deep research of pathogenic mechanism of GCRV-II, vaccine preparation, antiviral drug screening and prevention and control of grass carp viral hemorrhagic disease.

The invention belongs to the technical field of biological medicines, and provides application of DRAM1 as a diagnosis and treatment target for resisting non-alcoholic fatty liver disease related hepatocellular carcinoma in preparation of a kit, a carrier and a medicine aiming at the problem of lack of effective treatment targets of NAFLD-related HCC. As a target spot for resisting the non-alcoholic fatty liver disease related hepatocellular carcinoma, the expression level of the DRAM1 in liver tissues of non-alcoholic fatty liver disease related hepatocellular carcinoma patients and mice is increased. According to the application disclosed by the invention, research is developed aiming at the effect of the DRAM1 in the generation and development of NAFLD-related HCC, the analysis of TCGA liver cancer queue data and a GSE164760 data set is taken as an entry point, the influence of the DRAM1 on the diagnosis and prognosis of the liver cancer is comprehensively analyzed, and verification is carried out through a mouse in-vivo experiment, so that a new thought and a new target spot are provided for clinical diagnosis and treatment of the liver cancer.

The invention discloses application of MIGA2 as a therapeutic target in a medicine for preventing and treating Alzheimer's disease, and belongs to the technical field of biological medicine. The MIGA2 gene is used as a therapeutic target to be applied to development, screening or preparation of drugs for preventing and treating Alzheimer's disease. After an MIGA2 overexpression plasmid is adopted to transfect an Alzheimer's disease cell model, it is found that autophagy flow in cells can be promoted and accumulation of related toxic proteins can be reduced, it is proved that MIGA2 has the neuroprotective effect on the Alzheimer's disease, and a new way and exploration direction are provided for treatment of the Alzheimer's disease.

The invention relates to a cell collection method capable of simultaneously collecting three cells in a co-culture model, and belongs to the technical field of biology. The invention provides a cell collection method capable of simultaneously collecting three cells in a co-culture model, and the cell collection method comprises the following steps: after a three-cell co-culture model is constructed, taking out a Transwell chamber, retaining cells in the lower chamber, and collecting the cells in the lower chamber; respectively digesting the cells on the two sides of the Transwell cell membrane by using a trypsin solution with the concentration of 0.5 g / 100mL so as to respectively collect the cells on the two sides of the Transwell cell membrane. According to the cell collection method disclosed by the invention, the three cells in the three-cell co-culture model are simultaneously collected in a manner of digesting the cells on the two sides of the Transwell membrane step by step by using pancreatin, so that not only is the cell and consumable cost saved, but also the experimental synchronism of the three cells is ensured, and convenience is provided for optimizing the experimental process.

To provide a method for evaluating disposition and / or effect of a candidate compound in an in-vitro culture and / or suspension to predict in-vivo disposition and / or effect of the candidate compound.SOLUTION: A method comprises the steps of: providing a cell culture and / or suspension; exposing a candidate compound to the culture and / or suspension; exposing the culture and / or suspension to a culture medium providing an extracellular environment related to in vivo (the culture medium contains a certain component (e.g., protein or the like) at a concentration having characteristics (e.g., binding characteristics) similar to physiological concentration or physiologic concentration), wherein arbitrary combination of any of the "exposing steps" can occur in any order or simultaneously; and evaluating in-vitro disposition and / or effect of the candidate compound to predict in-vivo disposition and / or effect of the candidate compound.SELECTED DRAWING: None

Some methods of performing an assay comprise culturing target cells in one or more channels of one or more microfluidics chips, where each of the channel(s) can have a volume that is less than or equal to 100 microliters (μL). For each of one or more test liquids that each comprise a therapeutic reagent, the test liquid can flow over the cultured target cells in at least one of the channel(s) and, while the test liquid flows over the cultured target cells, data indicative of an interaction between the target cells over which the test liquid flows and the therapeutic reagent of the test liquid can be captured.

The invention discloses a lung squamous cell carcinoma drug discovery method and system based on disturbance response scanning analysis, and belongs to the field of biological medicines.The method comprises the steps that lung squamous cell carcinoma protein expression profile data is downloaded and preprocessed, a robust network module is constructed and multi-scale analysis and evaluation are conducted, and drug genomic data are obtained based on drug genomic data. Predicting the drug sensitivity of the patient by using machine learning, and generating a DRN through difference analysis of the drug sensitivity; predicting drug-target protein binding affinity in combination with deep learning, quantifying node sensitivity through a PRS technology, calculating a DPI disturbance score and ranking drug priorities; high-ranking drugs are screened through comprehensive sensitivity analysis and literature investigation; a drug for a lung squamous carcinoma cell line is screened out through a pre-experiment and is relocated. According to the framework developed by the invention, by integrating proteomics, pharmacogenomics and dynamic network analysis, systematic analysis is provided for relocation drug identification of lung squamous cell carcinoma, and good news is brought to treatment of lung squamous cell carcinoma.

The invention provides a method for constructing a chronic unpredictable negative stress model, the chronic unpredictable negative stress model and application of the chronic unpredictable negative stress model in mental disease research, and belongs to the field of brain organ in-vitro model construction. Through dual verification of a microelectrode array and single cell sequencing, an in-vitro brain organ model capable of simulating chronic unpredictable negative stress core characteristics is successfully constructed, and a potential neural network function reconstruction mechanism and a cell molecule basis of the in-vitro brain organ model are disclosed. The comprehensive research normal form breaks through the limitation of a traditional single technology platform, and an accurate and efficient innovative research platform highly related to human is provided for pathogenesis research of mental diseases, especially chronic stress related diseases such as depression and anxiety and development of novel treatment strategies.

To provide a new composition consisting of 100% natural matter, exerting a therapeutic or beneficial effect in the treatment of bone fragility, having a physiological mode of action.SOLUTION: The present invention provides a 100% natural product consisting of natural matrices exhibiting emerging properties, which enables re-establishing correct bone metabolism by correcting behavior of mesenchymal stem cells and re-establishing a correct balance between cell populations that allow bone growth or remodeling. The natural product consists of, for example, Equisetum flowering tops, Acacia, Malpighia fruit, coral skeleton, avian eggshell, Agave leaves, Cetraria stems, Agaricus, and calcium citrate.SELECTED DRAWING: None

The invention discloses an application of the number of neutrophils in predicting the curative effect of oncolytic viruses in treating tumors. In the application, the neutrophile granulocyte number level in the blood of a tumor patient is closely associated with the tumor treatment effect, and the applicable tumor syndromes are common, including melanoma, colorectal cancer, esophageal cancer, head and neck tumors, gastric cancer, biliary tract system tumors, sarcoma and other tumors. In the application, the critical value of the number of neutrophils for predicting the tumor treatment effect is 2 * 10 < 9 >-5.5 * 10 < 9 > / L, and the most preferable critical value is 4.0 * 10 < 9 > / L; the curative effect of OH2 single-drug treatment on tumor patients with the neutrophil number level below a critical value is better than that of tumor patients with the neutrophil number level above the critical value.

The present invention relates to a use of THBS1 as a novel combination drug target that can overcome drug resistance of a targeted anticancer agent. A THBS1 inhibitor according to the present invention inhibits the drug resistance of a target anticancer agent and thus increases an anticancer effect when administered in combination with a target anticancer agent. Accordingly, the present invention can overcome resistance to a targeted anticancer agent and increase a treatment success rate of anticancer drugs for cancer patients, thereby suggesting new possibilities for treatment strategies using targeted anticancer drugs and contributing to the realization of precision medicine.

The invention belongs to the technical field of biomedicine, and discloses an immortalized cell line for human kidney suspected cell carcinoma as well as a culture method and application of the immortalized cell line. The immortalized cell line for the human kidney suspected cell carcinoma, disclosed by the invention, is named as a human kidney suspected cell carcinoma cell line Loya a-710 (Homo sapiens), the classification name of the Latin name of the immortalized cell line is Chromophore sensor cell carcino: Loya a-710, and the preservation number of the immortalized cell line is CCTCC (China Center for Type Culture Collection) NO: C2025123. The human kidney suspected cell carcinoma cell line Loya-710 disclosed by the invention is used as an in-vitro model to rapidly grow in tissue culture, and mitochondrial mutation characteristics, a vesicle structure and a classical immunohistochemical marker of ChRCC are reserved. The invention provides a precious tool for further research on ChRCC heredity, molecules and biological characteristics, and also provides a powerful new model for mitochondrial diseases.

The invention relates to an application of a CTHRC1 inhibitor in preparation of a medicine for preventing and / or treating arthritis. Specifically, the invention provides application of an inhibitor or an antagonist of a CTHRC1 gene or a protein thereof, the inhibitor or the antagonist is used for preparing a composition or a preparation, and the composition or the preparation is used for (a) preventing and / or treating arthritis-related diseases; and / or (b) inhibiting cartilage cell senescence.

The invention relates to a retina nerve and blood vessel unit in-vitro three-culture model and a preparation method thereof, and belongs to the technical field of biology. The invention provides an in-vitro three-culture model of a retina nerve and blood vessel unit. The in-vitro three-culture model is obtained by carrying out in-vitro Transwell indirect co-culture on retina microvascular endothelial cells, retina ganglion cells and retina Muller cells. The in-vitro three-culture model of the retina nerve and blood vessel unit is based on a three-cell indirect co-culture method, retina microvascular endothelial cells, retina ganglion cells and retina Muller cells are simultaneously incorporated by utilizing Transwell, and the three cells are in indirect contact. The in-vitro three-culture model of the retina nerve and blood vessel unit can be used for more objectively simulating pathophysiological states of various cells of the retina nerve and blood vessel unit, so that common pathophysiological changes of mutual dependence and interaction of the three cells under in-vitro conditions can be observed.

The invention discloses an application of EIF5B in treatment of leukemia. According to the application, the translation initiation factor EIF5B which is generally highly expressed in various subtype AML patients is found for the first time, specifically participates in maintaining the function of an AML cell line, does not influence the function of normal HSPC, and is expected to become a broad-spectrum AML treatment target.

The invention discloses a construction method and application of an in-vitro callus-like organ, the survival rate of the organ is improved by improving freeze-formed bio-ink, and a stable directional channel structure is further prepared, so that the internal mass transfer problem of the callus-like organ is improved, and the material exchange efficiency is improved. The forming mode of the callus-like organ is simple and effective, the stent material is easy to prepare, and the callus-like organ has mature cross-linking and printing characteristics, is expected to be applied to drug screening research or bone defect repair, is clear in process and simple in composition, and has relatively high operability.

Disclosed are a method, a device, and an information processing program for determining, by using refractive index distribution data pertaining to an object to be observed, the region of a cell that has undergone programmed cell death in the object to be observed.

The invention provides a culture medium and a culture method for culturing human primary B lymphoma cells. The culture medium for culturing the human primary B lymphoma cells, disclosed by the invention, is prepared from an anti-immune globulin M antibody, a recombinant human CD40 ligand, CpG oligodeoxynucleotide 2006, superoxide dismutase, interleukin-2, interleukin-21 and interleukin-4. By using the culture medium and the culture method disclosed by the invention, effective and rapid amplification of the B lymphoma cells can be realized, the B lymphoma cells obtained by amplification maintain pathological characteristics of patients, the culture success rate and the amplification rate of the B lymphoma cells are improved, and a research basis can be provided for personalized treatment of the patients. The invention also provides B lymphoma cells obtained by in-vitro culture of the culture medium, and a method and application of the B lymphoma cells in curative effect evaluation and screening of drugs.

The invention relates to the technical field of biology, in particular to a composition for preparing a brain organ, the brain organ and application of the brain organ. The invention further discloses a construction method of the brain organ, and on the basis of the method, different stem cells such as ESCs and iPSCs can be utilized to stably construct the three-dimensional brain organ model capable of simulating the medulla oblongata trigeminal nerve. The invention further discloses an organoid assembly which has important application potential in the fields of research on development, functions and related diseases of brain nuclei, drug discovery and the like.

The present invention relates to methods using trained classifier for assessing potency of a compound to revert the phenotype of a myotube exhibiting features of a neuromuscular disorder of interest into a healthy phenotype, for predicting the ability of a compound to treat a neuromuscular disorder of interest, for monitoring the response to a therapeutic compound of a patient affected with a neuromuscular disorder of interest, for selecting a patient affected with a neuromuscular disorder of interest for a treatment with a therapeutic compound or for determining whether a patient affected with a neuromuscular disorder of interest is susceptible to benefit from a treatment with a therapeutic compound, or for diagnosing a neuromuscular disorder of interest.

The invention discloses an engineered macrophage and a pharmaceutical composition and application thereof, and CCM3 expression in the engineered macrophage is inhibited, so that the engineered macrophage is polarized towards the M2 direction or the engineered macrophage is an M2 type macrophage. Besides, the invention further develops a temperature-sensitive cell-loaded hydrogel preparation which can promote polarization of macrophages in the M2 direction by inhibiting expression of signal molecules CCM3 on adhesion spots, and the temperature-sensitive cell-loaded hydrogel preparation can promote bone defect immune osteogenesis through local injection.

The invention discloses a double-chamber micro-fluidic organ chip, a preparation method and application, and belongs to the technical field of biological materials. The double-chamber micro-fluidic organ chip sequentially comprises a top layer, an upper layer, a middle layer and a lower layer from top to bottom, cavities are formed in the upper layer and the lower layer, and micropore arrays for accommodating biological samples are arranged in the cavities; the chip further comprises a plurality of circulation channels which can be respectively communicated with the upper layer chamber and the lower layer chamber, so that a biological sample enters and exits from the micropore array; and the middle layer is a semi-permeable porous membrane. The micro-fluidic organ chip can be used for establishing a metabolic disease model, promoting interaction between organs and realizing space-time dynamic change analysis of tissues and organs.

The invention relates to the technical field of biomedicine, in particular to a mouse intrahepatic bile duct cancer cell strain and a construction method and application thereof, the cell strain is named as mouse intrahepatic bile duct cancer cell strain KP-ICC and preserved in China Center for Type Culture Collection (CCTCC), and the preservation number is CCTCC NO: C202574; the cell strain is derived from a KrasG12D / Tp53flox / flox C57BL / 6J mouse, a spontaneous tumor model is constructed through high-pressure hydrodynamic tail vein injection of pT3-Cre and a sleep beauty transposase plasmid, and the spontaneous tumor model is obtained through in-vitro culture, passage, monoclonal screening and tumorigenicity verification. The KP-ICC cell strain naturally has chemotherapy-immune combined treatment drug resistance and ferroptosis resistance characteristics, and can be widely applied to the fields of intrahepatic cholangiocarcinoma drug resistance mechanism research, drug resistance reversing, combined treatment drug development, drug resistance animal model establishment and the like.

The invention belongs to the technical field of biology, and particularly relates to a human metapneumovirus mouse adapted strain and application thereof. Compared with a wild strain, the strain has higher susceptibility to animals; the strain can be used for treating BALB / c mice and can cause typical clinical symptoms and even death, for example, after the strain infects the BALB / c mice, the disease symptoms are obvious, the weight of 83% infected mice is severely reduced to 75% or below and reaches the humanity killing standard, and the death rate reaches 50% or above 4 days after the strain infects the BALB / c mice; the strain can be used for constructing a cell model or an animal model of human metapneumovirus infection or diseases caused by the human metapneumovirus infection, and is further used for screening drugs for preventing and / or treating the human metapneumovirus infection or the diseases caused by the human metapneumovirus infection. In addition, the strain can also be used for preparing medicines for preventing and / or treating human metapneumovirus infection or diseases caused by the human metapneumovirus infection, preparing antibodies or antiserum for resisting the human metapneumovirus and the like.

Provided herein are methods for one or more of a) modulating an immune response to a tumor cell in a patient, b) treating cancer in a cancer patient; or c) eliciting an anti-tumor response in a patient, comprising modulating the expression or activity of Junction Adhesion Molecule Like (JAML).

The present disclosure relates generally to methods of inhibiting a tripartite VAP-A, ORP3 and Rab7 (VOR) protein complex in multicellular organisms, to methods of identifying agents which inhibit such complex and to the medical use of those agents. Inhibition of the VOR complex causes interference with at least one mechanism of intercellular communication, wherein the intercellular communication is mediated by receptor-ligand interaction and / or EVs, and viral infection involving the transport of endocytosed biomaterials to the nucleus of recipient cells.

The invention relates to the fields of biology, medicine and clinic. The invention specifically relates to application of a reagent targeting an eIF2alpha / ATF4 pathway in treatment of hepatic fibrosis diseases. Based on research of the inventor of the invention, on one hand, the invention discloses application of a reagent for targeted inhibition of an eIF2alpha / ATF4 pathway in preparation of drugs for treating hepatic fibrosis diseases, or application of the reagent in preparation of drugs for preventing liver cirrhosis and / or liver cancer; on the other hand, the invention discloses an application of the eIF2alpha / ATF4 pathway protein and / or the coding gene thereof in screening of drugs for treating hepatic fibrosis diseases, or an application in screening of drugs for preventing liver cirrhosis and / or liver cancer. Another aspect of the invention discloses a pharmaceutical composition comprising an agent for targeted inhibition of expression or activity of an eIF2alpha / ATF4 pathway protein; the invention has considerable application prospects in clinical treatment of hepatic fibrosis diseases.

The invention belongs to the technical field of biomedicine, and relates to a method for constructing a mouse embryo-derived hypothalamic organ model and application, the invention proposes that a mouse embryo is used for constructing a hypothalamic organ for the first time, and the mouse embryo has a definite development time sequence and genetic operability; the naturally retained vascular endothelial cells and multilineage precursor cells provide unique advantages for constructing a three-dimensional organ containing multiple nucleuses such as a preoptic region, a paraventricular nucleus, an arcuate nucleus and a supraoptic nucleus, and the model not only breaks through the nucleus coverage limitation of the existing iPSCs organ, but also can be used for constructing the three-dimensional organ containing multiple nucleuses such as the preoptic region, the paraventricular nucleus, the arcuate nucleus, the supraoptic nucleus and the like by reconstructing a nerve-blood vessel unit. High-fidelity simulation of complex physiological functions of the hypothalamus is realized, and an irreplaceable technical platform is provided for mechanism analysis of neuroendocrine diseases and high-throughput screening of drugs.

The invention discloses an application of a THBS1 inhibitor in preparation of a medicine for preventing or treating lung tissue inflammation induced by novel coronavirus, and provides a related medicine, application and a method, the THBS1 gene inhibitor or a TSP-1 protein inhibitor is used for treating the lung tissue inflammation infected by SARS-CoV-2, the effect is remarkable, and the medicine can be used for preparing medicines for preventing or treating the lung tissue inflammation induced by the novel coronavirus. The SARS-CoV-2 gene is a novel target for treating severe pneumonia caused by SARS-CoV-2 infection.

The present invention provides for methods of epigenetic analysis. In some cases, the methods may include obtaining a sample comprising a nucleic acid sequence. In some cases, the nucleic acid sequence may comprise one or more epigenetic marks. The methods may include performing a sequencing. The methods may include distinguishing a hydroxymethylated base from a methylated base.